Antiplatelet combinations for prevention of atherothrombotic events

References

• WareJAHeistadDDSeminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactionsN Engl J Med199332896286358429855
   PubMed Web of Science ®Google Scholar
• KwaanHCSamamaMMThe significance of endothelial heterogeneity in thrombosis and hemostasisSemin Thromb Hemost201036328630020490979
   PubMed Web of Science ®Google Scholar
• FusterVSteinBAmbroseJAAtherosclerotic plaque rupture and thrombosis. Evolving conceptsCirculation1990823 SupplII47II592203564
   PubMed Web of Science ®Google Scholar
• SaelmanEUNieuwenhuisHKHeseKMPlatelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (α2β1-integrin)Blood1994835124412508118028
   PubMed Web of Science ®Google Scholar
• SavageBGinsbergMHRuggeriZMInfluence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flowBlood19999482704271510515874
   PubMed Web of Science ®Google Scholar
• SternDMKaiserENawrothPRegulation of the coagulation system by vascular endothelial cellsHaemostasis19881846202214
   Google Scholar
• JinJDanielJLKunapuliSPMolecular basis for ADP-induced platelet activation: II. The P2YI receptor mediates ADP-induced intracellular calcium mobilization and shape change in plateletsJ Biol Chem19982734203020349442040
   PubMed Web of Science ®Google Scholar
• RuggeriZMPlatelets in atherothrombosisNat Med20028111227123412411949
   PubMed Web of Science ®Google Scholar
• AngiolilloDJGuzmanLABassTACurrent antiplatelet therapies: Benefits and limitationsAm Heart J20081562 SupplS3S918657680
   PubMed Web of Science ®Google Scholar
• MehtaSRYousufSShort- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary interventionJ Am Coll Cardiol2003414 Suppl S79S88S12644345
   PubMed Web of Science ®Google Scholar
• BaigentCBlackwellLCollinsRAntithrombotic Trialists’ (ATT) CollaborationAspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trialsLancet200937396781849186019482214
   PubMed Web of Science ®Google Scholar
• WolffTMillerTKoSAspirin for the primary prevention of cardiovascular events: An update of the evidence for the US Preventive Services Task ForceAnn Intern Med2009150640541019293073
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task ForceAspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statementAnn Intern Med2009150639640419293072
   PubMed Web of Science ®Google Scholar
• SaccoMPellegriniFRoncaglioniMCPrimary prevention of cardiovascular events with low-dose ASA and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trialDiabetes Care200326123264327214633812
   PubMed Web of Science ®Google Scholar
• RidkerPMCookNRLeeIMA randomized trial of low-dose ASA in the primary prevention of cardiovascular disease in womenN Engl J Med2005352131293130415753114
   PubMed Web of Science ®Google Scholar
• FowkesFGRPriceJFStewartMCWAspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index, a randomized controlled trialJAMA2010303984184820197530
   PubMed Web of Science ®Google Scholar
• BergerJSRoncaglioniMCAvanziniFPangrazziITognoniGBrownDLAspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trialsJAMA2006295330631316418466
   PubMed Web of Science ®Google Scholar
• De BerardisGSaccoMStrippoliGFAspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trialsBMJ2009339b453119897665
   PubMed Web of Science ®Google Scholar
• YounisNWilliamsSAmmoriBSoranHRole of ASA in the primary prevention of cardiovascular disease in diabetes mellitus: A meta-analysisExpert Opin Pharmacother20101191459146620429671
   PubMed Web of Science ®Google Scholar
• LipGYHFelmedenDCAntiplatelet agents and anticoagulants for hypertensionCochrane Database Syst Rev20043CD00318615266473
   PubMedGoogle Scholar
• BelchJMacCuishACampbellIThe prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of ASA and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseBMJ2008337a184018927173
   PubMed Web of Science ®Google Scholar
• OgawaHNakayamaMMorimotoTLow-dose ASA for primary prevention of atherosclerotic events in patients with type 2 diabetesJAMA2008300182134214118997198
   PubMed Web of Science ®Google Scholar
• MohlerERIIICombination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy ASA, clopidogrel, or both?Cath Cardiovasc Interv200974Suppl 1S1S6
   PubMed Web of Science ®Google Scholar
• McQuaidKRLaineLSystematic review and meta-analysis of adverse events of low-dose ASA and clopidogrel in randomized controlled trialsAm J Med2006119862463816887404
   PubMed Web of Science ®Google Scholar
• PignoneMAlbertsMJColwellJAAspirin for primary prevention of cardiovascular events in people with diabetesJ Am Coll Cardiol201055252878288620579547
   PubMed Web of Science ®Google Scholar
• NicolucciADe BerardisGSaccoMTognoniGAHA/ADA vs ESC/EASD recommendations on ASA as a primary prevention strategy in people with diabetes: How the same data generate divergent conclusionsEur Heart J200728161925192717604291
   PubMed Web of Science ®Google Scholar
• BarnettHBurrillPIheanachoIDon’t use ASA for primary prevention of cardiovascular diseaseBMJ2010340c180520410163
   PubMedGoogle Scholar
• Garcia RodriguezLAHernandez-DiazSde AbajoFJAssociation between ASA and upper gastrointestinal complications: Systematic review of epidemiologic studiesBr J Clin Pharmacol200152556357111736865
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus ASA in patients at risk of ischaemic events (CAPRIE)Lancet19963489038132913398918275
   PubMed Web of Science ®Google Scholar
• ScrutinioDCimminielloCMarubiniEPitzalisMVDi BiaseMRizzonPTiclopidine versus ASA after myocardial infarction (STAMI) trialJ Am Coll Cardiol20013751259126511300432
   PubMed Web of Science ®Google Scholar
• HassWKEastonJDAdamsHPJrA randomized trial comparing ticlopidine hydrochloride with ASA for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study GroupN Engl J Med198932185015072761587
   PubMed Web of Science ®Google Scholar
• Biondi ZoccaiGLotrionteMGaitaFAlternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?World J Cardiol20102613113421160730
   PubMedGoogle Scholar
  CravenLLMiss Valley Med J195678521321513358612
   PubMedGoogle Scholar
• HarkerLAMarzecUMKellyABClopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by ASA in nonhuman primatesCirculation19989822246124699832493
   PubMed Web of Science ®Google Scholar
• LeonMBBaimDSPopmaJJA clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study InvestigatorsN Engl J Med199833923166516719834303
   PubMed Web of Science ®Google Scholar
• BhattDLFoxKAHackeWClopidogrel and ASA versus ASA alone for the prevention of atherothrombotic eventsN Engl J Med2006354161706171716531616
   PubMed Web of Science ®Google Scholar
• BergerPBBhattDLFusterVBleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialCirculation2010121232575258320516378
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJfor the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) InvestigatorsEffects of pretreatment with clopidogrel and ASA followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJTFryETDeLagoAWilmerCfor the CREDO Investigators, Clopidogrel for the Reduction of Events During ObservationEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• SabatineMSCannonCPGibsonCMfor the CLARITY-TIMI 28 InvestigatorsAddition of clopidogrel to ASA and fibrinolytic therapy for myocardial infarction with ST-segment elevationN Engl J Med2005352121179118915758000
   PubMed Web of Science ®Google Scholar
• HeltonTJBavryAAKumbhaniDJDuggalSRoukozHBhattDLIncremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: A meta-analysis of randomized trialsAm J Cardiovasc Drugs20077428929717696569
   PubMed Web of Science ®Google Scholar
• GurbelPATantryUSPrasugrel, a third generation thienopyridine and potent platelet inhibitorCurr Opin Investig Drugs200893324336
   PubMedGoogle Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• CannonCPHarringtonRAJamesFComparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind studyLancet2010375971128329320079528
   PubMed Web of Science ®Google Scholar
• DienerHCBogousslavskyJBrassLMfor the MATCH InvestigatorsAspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trialLancet2004364943133133715276392
   PubMed Web of Science ®Google Scholar
• ColletJPAoutMAlantarAReal-life management of dual antiplatelet therapy interruption: The REGINA surveyArch Cardiovasc Dis20091021069771019913771
   PubMed Web of Science ®Google Scholar
• SenstBLAchusimLEGenestRPPractical approach to determining costs and frequency of adverse drug events in a health care networkAm J Health Syst Pharm200158121126113211449856
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• SteinerJFEarnestMAThe language of medication-takingAnn Intern Med20001321192693010836931
   PubMed Web of Science ®Google Scholar
• BaileyWCRichardsJMJrBrooksCMSoongSJWindsorRAManzellaBAA randomized trial to improve self-management practices of adults with asthmaArch Intern Med19901508166416682200380
   PubMedGoogle Scholar
• MacIntyreCRGoebelKBrownGVSkullSStarrMFullinfawROA randomised controlled clinical trial of the efficacy of family based direct observation of anti-tuberculosis treatment in an urban, developed-country settingInt J Tuberc Lung Dis20037984885412971668
   PubMed Web of Science ®Google Scholar
• YusufSPaisPAfzalRThe Indian Polycap Study (TIPS)Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trialLancet200937396721341135119339045
   PubMed Web of Science ®Google Scholar
• HaynesRBAcklooESahotaNMcDonaldHPYaoXInterventions for enhancing medication adherenceCochrane Database Syst Rev20082CD00001118425859
   PubMed Web of Science ®Google Scholar
• GreenbergRNOverview of patient compliance with medication dosing: A literature reviewClin Ther1984655925996383611
   PubMed Web of Science ®Google Scholar
• LenzTlHillemanDEAggrenox: A fixed-dose combination of ASA and dipyridamoleAnn Pharmacother200034111283129011098344
   PubMed Web of Science ®Google Scholar
• SerebruanyVLMalininAPokovAAntiplatelet profiles of the fixed dose combination of extended release dipyridamole and low-dose ASA compared with clopidogrel with or without ASA in patients with type 2 diabetes and history of transient ischemic attack: A randomized, single bind, 30-day trialClin Ther200830224925918343263
   PubMed Web of Science ®Google Scholar